These results therefore clearly demonstrated that the expression of ITGB2, VEGFA, CLDN4, OCLN, and SPP1 were significantly correlated with poorer clinical outcomes in serous ovarian cancer. This evidence concerns the gene CLDN4 and ovarian serous adenocarcinoma.